<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Biological activities as antihypertensive and antioxidant (AO) values were quantified in FPHs samples as: (a) in vitro Angiotensin I-converting enzyme (ACE) inhibitory activity (
 <italic class="italic">I
  <sub class="sub">ACE</sub>
 </italic>) using the protocol that was defined by Estévez et al. [
 <xref rid="B56-marinedrugs-17-00139" ref-type="bibr" class="xref">56</xref>] and IC
 <sub class="sub">50</sub> values (protein-hydrolysate concentration that generates 50% of 
 <italic class="italic">I
  <sub class="sub">ACE</sub>
 </italic>), calculated according dose-response modelling [
 <xref rid="B28-marinedrugs-17-00139" ref-type="bibr" class="xref">28</xref>]; (b) 1,1-Diphenyl-2-picryhydrazyl (DPPH) radical-scavenging ability, following a microplate protocol [
 <xref rid="B57-marinedrugs-17-00139" ref-type="bibr" class="xref">57</xref>]; (c) ABTS (2,2′-azinobis-(3-ethyl-benzothiazoline-6-sulphonic acid) bleaching method at a microplate scale [
 <xref rid="B57-marinedrugs-17-00139" ref-type="bibr" class="xref">57</xref>]; and, (d) Crocin bleaching assay also employing an optimised microplate protocol [
 <xref rid="B58-marinedrugs-17-00139" ref-type="bibr" class="xref">58</xref>]. All of the antihypertensive and AO determinations were done in triplicate, employing FPHs samples at concentration of 1 g/L of soluble protein.
</p>
